Skip to main content
. 2014 Oct;351(1):44–53. doi: 10.1124/jpet.114.216036

Fig. 2.

Fig. 2.

(A and B) Changes in MAP (A) and HR (B) after intra-RVLM microinjections of either DMSO (diluted 1:16 in ACSF) or PD98059 (50 μmol) at 0 minutes and subsequent vehicle (methyl acetate) or Abn CBD (0.4 μg) microinjection. Pretreatment with PD98059 abrogated the GPR18 (Abn CBD)-mediated hypotensive response. (C and D) AUC data generated from the time course values over the pretreatment (0–30 minutes) and treatment (30–60 minutes) periods. The left two bars in the AUC graph show pretreatment. Compared with vehicle, PD98059 caused significant elevation in BP (A and C). Abn CBD caused significant reduction in BP, and this response was abrogated in PD98059 pretreated rats (A and C). All pretreatment data obtained from groups of rats that received the same drug were combined for clarity. Six rats per group were used except DMSO plus vehicle or Abn CBD groups (n = 3 each). *P < 0.05 versus control (vehicle); #P < 0.05 versus Abn CBD. AbC, Abn CBD; ACSF, artificial cerebrospinal fluid; AUC, area under the curve; ΔHR, change in HR; ΔMAP, change in MAP; DM, DMSO; PD, PD98059; Veh, vehicle (methyl acetate).